Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance

Reuters

昨天

Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance

Applied DNA Sciences Inc. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-057222), on June 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2541867997"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541867997\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2541867997?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-07 02:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541867997","market":"nz","top_or_hot":-1,"title":"Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APDN\">Applied DNA Sciences Inc</a>. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-057222), on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-07 02:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APDN\">Applied DNA Sciences Inc</a>. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-057222), on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDLcgzk2Z:1","article_id":"2541867997","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541867997","pubTimestamp":1749234557,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Applied DNA Sciences Inc. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","BK4121":"生命科学工具和服务","APDN":"Applied DNA Sciences Inc"},"translate_title":"由于不遵守投标价格规则，Applied DNA Sciences可能面临纳斯达克退市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APDN":0.9},"content_text":"Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance\n    \n\nApplied DNA Sciences Inc. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-057222), on June 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}